Correction: Fadraciclib (CYC065), a novel CDK inhibitor, targets key pro-survival and oncogenic pathways in cancer.

Where this comes from

• Record sourced from PubMed, PMID 33956908.
• Also identified by DOI 10.1371/journal.pone.0251671 and PMC identifier 8101907.
• No licence information is recorded for this record.
• Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.